Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2006

Teva Granted Tentative Approval for Generic Risperdal Oral Solution

  • Teva Pharmaceutical Industries received tentative approval in response to the abbreviated new drug application filed to market the company’s generic version of Janssen’s Risperdal® (Risperidone) Oral Solution, 1 mg/mL. Final approval is expected upon expiry of Risperdal’s patent on December 29, 2007.

    Upon final approval, Teva’s Risperidone Oral Solution will be the AA-rated generic equivalent of Risperdal, indicated for treatment of schizophrenia and acute manic or mixed episodes associated with bipolar I disorder.

    Annual brand product sales in the U.S. were approximately $66 million for the 12-month period, which ended on June 2006, based on IMS data, reports Teva.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »